Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021

Mark W. Tenforde; Wesley H. Self; Eric A. Naioti; Adit A. Ginde; David J. Douin; Samantha M. Olson; H. Keipp Talbot; Jonathan D. Casey; Nicholas M. Mohr; Anne Zepeski; Manjusha Gaglani; Tresa McNeal; Shekhar Ghamande; Nathan I. Shapiro; Kevin W. Gibbs; D. Clark Files; David N. Hager; Arber Shehu; Matthew E. Prekker; Heidi L. Erickson; Michelle N. Gong; Amira Mohamed; Daniel J. Henning; Jay S. Steingrub; Ithan D. Peltan; Samuel M. Brown; Emily T. Martin; Arnold S. Monto; Akram Khan; Catherine L. Hough; Laurence W. Busse; Caitlin C. ten Lohuis; Abhijit Duggal; Jennifer G. Wilson; Alexandra June Gordon; Nida Qadir; Steven Y. Chang; Christopher Mallow; Carolina Rivas; Hilary M. Babcock; Jennie H. Kwon; Matthew C. Exline; Natasha Halasa; James D. Chappell; Adam S. Lauring; Carlos G. Grijalva; Todd W. Rice; Ian D. Jones; William B. Stubblefield; Adrienne Baughman; Kelsey N. Womack; Christopher J. Lindsell; Kimberly W. Hart; Yuwei Zhu; Meagan Stephenson; Stephanie J. Schrag; Miwako Kobayashi; Jennifer R. Verani; Manish M. Patel

doi:10.15585/MMWR.MM7034E2

Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021

Mark W. Tenforde, Wesley H. Self, Eric A. Naioti, Adit A. Ginde, David J. Douin, Samantha M. Olson, H. Keipp Talbot, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Manjusha Gaglani, Tresa McNeal, Shekhar Ghamande, Nathan I. Shapiro, Kevin W. Gibbs, D. Clark Files, David N. Hager, Arber Shehu, Matthew E. Prekker, Heidi L. EricksonMichelle N. Gong, Amira Mohamed, Daniel J. Henning, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Arnold S. Monto, Akram Khan, Catherine L. Hough, Laurence W. Busse, Caitlin C. ten Lohuis, Abhijit Duggal, Jennifer G. Wilson, Alexandra June Gordon, Nida Qadir, Steven Y. Chang, Christopher Mallow, Carolina Rivas, Hilary M. Babcock, Jennie H. Kwon, Matthew C. Exline, Natasha Halasa, James D. Chappell, Adam S. Lauring, Carlos G. Grijalva, Todd W. Rice, Ian D. Jones, William B. Stubblefield, Adrienne Baughman, Kelsey N. Womack, Christopher J. Lindsell, Kimberly W. Hart, Yuwei Zhu, Meagan Stephenson, Stephanie J. Schrag, Miwako Kobayashi, Jennifer R. Verani, Manish M. Patel

Research output: Contribution to journal › Review article › peer-review

157 Scopus citations

Abstract

In a multistate network that enrolled adults hospitalized during March-July 2021, effectiveness of 2 doses of mRNA vaccine against COVID-19-associated hospitalization was sustained over a follow-up period of 24 weeks (approximately 6 months). These findings of sustained VE were consistent among subgroups at highest risk for severe outcomes from COVID-19, including older adults, adults with three or more chronic medical conditions, and those with immunocompromising conditions. Overall VE in adults with immunocompromising conditions was lower than that in those without immunocompromising conditions but was sustained over time in both populations.

Original language	English
Pages (from-to)	1156-1162
Number of pages	7
Journal	Morbidity and Mortality Weekly Report
Volume	70
Issue number	34
DOIs	https://doi.org/10.15585/MMWR.MM7034E2
State	Published - Aug 2021

Access to Document

10.15585/MMWR.MM7034E2

Cite this

Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., Ghamande, S., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., ... Patel, M. M. (2021). Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021. Morbidity and Mortality Weekly Report, 70(34), 1156-1162. https://doi.org/10.15585/MMWR.MM7034E2

@article{5c49d8dcec074c5b8e8a28281b16cf68,

title = "Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021",

abstract = "In a multistate network that enrolled adults hospitalized during March-July 2021, effectiveness of 2 doses of mRNA vaccine against COVID-19-associated hospitalization was sustained over a follow-up period of 24 weeks (approximately 6 months). These findings of sustained VE were consistent among subgroups at highest risk for severe outcomes from COVID-19, including older adults, adults with three or more chronic medical conditions, and those with immunocompromising conditions. Overall VE in adults with immunocompromising conditions was lower than that in those without immunocompromising conditions but was sustained over time in both populations.",

author = "Tenforde, {Mark W.} and Self, {Wesley H.} and Naioti, {Eric A.} and Ginde, {Adit A.} and Douin, {David J.} and Olson, {Samantha M.} and Talbot, {H. Keipp} and Casey, {Jonathan D.} and Mohr, {Nicholas M.} and Anne Zepeski and Manjusha Gaglani and Tresa McNeal and Shekhar Ghamande and Shapiro, {Nathan I.} and Gibbs, {Kevin W.} and Files, {D. Clark} and Hager, {David N.} and Arber Shehu and Prekker, {Matthew E.} and Erickson, {Heidi L.} and Gong, {Michelle N.} and Amira Mohamed and Henning, {Daniel J.} and Steingrub, {Jay S.} and Peltan, {Ithan D.} and Brown, {Samuel M.} and Martin, {Emily T.} and Monto, {Arnold S.} and Akram Khan and Hough, {Catherine L.} and Busse, {Laurence W.} and {ten Lohuis}, {Caitlin C.} and Abhijit Duggal and Wilson, {Jennifer G.} and Gordon, {Alexandra June} and Nida Qadir and Chang, {Steven Y.} and Christopher Mallow and Carolina Rivas and Babcock, {Hilary M.} and Kwon, {Jennie H.} and Exline, {Matthew C.} and Natasha Halasa and Chappell, {James D.} and Lauring, {Adam S.} and Grijalva, {Carlos G.} and Rice, {Todd W.} and Jones, {Ian D.} and Stubblefield, {William B.} and Adrienne Baughman and Womack, {Kelsey N.} and Lindsell, {Christopher J.} and Hart, {Kimberly W.} and Yuwei Zhu and Meagan Stephenson and Schrag, {Stephanie J.} and Miwako Kobayashi and Verani, {Jennifer R.} and Patel, {Manish M.}",

year = "2021",

month = aug,

doi = "10.15585/MMWR.MM7034E2",

language = "English",

volume = "70",

pages = "1156--1162",

journal = "Morbidity and Mortality Weekly Report",

issn = "0149-2195",

number = "34",

}

Tenforde, MW, Self, WH, Naioti, EA, Ginde, AA, Douin, DJ, Olson, SM, Talbot, HK, Casey, JD, Mohr, NM, Zepeski, A, Gaglani, M, McNeal, T, Ghamande, S, Shapiro, NI, Gibbs, KW, Files, DC, Hager, DN, Shehu, A, Prekker, ME, Erickson, HL, Gong, MN, Mohamed, A, Henning, DJ, Steingrub, JS, Peltan, ID, Brown, SM, Martin, ET, Monto, AS, Khan, A, Hough, CL, Busse, LW, ten Lohuis, CC, Duggal, A, Wilson, JG, Gordon, AJ, Qadir, N, Chang, SY, Mallow, C, Rivas, C, Babcock, HM , Kwon, JH, Exline, MC, Halasa, N, Chappell, JD, Lauring, AS, Grijalva, CG, Rice, TW, Jones, ID, Stubblefield, WB, Baughman, A, Womack, KN, Lindsell, CJ, Hart, KW, Zhu, Y, Stephenson, M, Schrag, SJ, Kobayashi, M, Verani, JR & Patel, MM 2021, 'Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021', Morbidity and Mortality Weekly Report, vol. 70, no. 34, pp. 1156-1162. https://doi.org/10.15585/MMWR.MM7034E2

Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021. / Tenforde, Mark W.; Self, Wesley H.; Naioti, Eric A. et al.
In: Morbidity and Mortality Weekly Report, Vol. 70, No. 34, 08.2021, p. 1156-1162.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021

AU - Tenforde, Mark W.

AU - Self, Wesley H.

AU - Naioti, Eric A.

AU - Ginde, Adit A.

AU - Douin, David J.

AU - Olson, Samantha M.

AU - Talbot, H. Keipp

AU - Casey, Jonathan D.

AU - Mohr, Nicholas M.

AU - Zepeski, Anne

AU - Gaglani, Manjusha

AU - McNeal, Tresa

AU - Ghamande, Shekhar

AU - Shapiro, Nathan I.

AU - Gibbs, Kevin W.

AU - Files, D. Clark

AU - Hager, David N.

AU - Shehu, Arber

AU - Prekker, Matthew E.

AU - Erickson, Heidi L.

AU - Gong, Michelle N.

AU - Mohamed, Amira

AU - Henning, Daniel J.

AU - Steingrub, Jay S.

AU - Peltan, Ithan D.

AU - Brown, Samuel M.

AU - Martin, Emily T.

AU - Monto, Arnold S.

AU - Khan, Akram

AU - Hough, Catherine L.

AU - Busse, Laurence W.

AU - ten Lohuis, Caitlin C.

AU - Duggal, Abhijit

AU - Wilson, Jennifer G.

AU - Gordon, Alexandra June

AU - Qadir, Nida

AU - Chang, Steven Y.

AU - Mallow, Christopher

AU - Rivas, Carolina

AU - Babcock, Hilary M.

AU - Kwon, Jennie H.

AU - Exline, Matthew C.

AU - Halasa, Natasha

AU - Chappell, James D.

AU - Lauring, Adam S.

AU - Grijalva, Carlos G.

AU - Rice, Todd W.

AU - Jones, Ian D.

AU - Stubblefield, William B.

AU - Baughman, Adrienne

AU - Womack, Kelsey N.

AU - Lindsell, Christopher J.

AU - Hart, Kimberly W.

AU - Zhu, Yuwei

AU - Stephenson, Meagan

AU - Schrag, Stephanie J.

AU - Kobayashi, Miwako

AU - Verani, Jennifer R.

AU - Patel, Manish M.

PY - 2021/8

Y1 - 2021/8

N2 - In a multistate network that enrolled adults hospitalized during March-July 2021, effectiveness of 2 doses of mRNA vaccine against COVID-19-associated hospitalization was sustained over a follow-up period of 24 weeks (approximately 6 months). These findings of sustained VE were consistent among subgroups at highest risk for severe outcomes from COVID-19, including older adults, adults with three or more chronic medical conditions, and those with immunocompromising conditions. Overall VE in adults with immunocompromising conditions was lower than that in those without immunocompromising conditions but was sustained over time in both populations.

AB - In a multistate network that enrolled adults hospitalized during March-July 2021, effectiveness of 2 doses of mRNA vaccine against COVID-19-associated hospitalization was sustained over a follow-up period of 24 weeks (approximately 6 months). These findings of sustained VE were consistent among subgroups at highest risk for severe outcomes from COVID-19, including older adults, adults with three or more chronic medical conditions, and those with immunocompromising conditions. Overall VE in adults with immunocompromising conditions was lower than that in those without immunocompromising conditions but was sustained over time in both populations.

UR - http://www.scopus.com/inward/record.url?scp=85114093646&partnerID=8YFLogxK

U2 - 10.15585/MMWR.MM7034E2

DO - 10.15585/MMWR.MM7034E2

M3 - Review article

C2 - 34437524

AN - SCOPUS:85114093646

SN - 0149-2195

VL - 70

SP - 1156

EP - 1162

JO - Morbidity and Mortality Weekly Report

JF - Morbidity and Mortality Weekly Report

IS - 34

ER -

Sustained effectiveness of pfizer-biontech and moderna vaccines against covid-19 associated hospitalizations among adults - united states, march-july 2021

Abstract

Access to Document

Other files and links

Fingerprint

Cite this